 |
Journal articles
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
Abstract : Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
Cited literature [17 references]
https://www.hal.inserm.fr/inserm-00850497
Contributor : Ed. Bmc Connect in order to contact the contributor
Submitted on : Tuesday, August 6, 2013 - 9:09:07 PM
Last modification on : Tuesday, October 19, 2021 - 4:17:35 PM
Long-term archiving on: : Wednesday, April 5, 2017 - 7:44:34 PM
Contributor : Ed. Bmc Connect in order to contact the contributor
Submitted on : Tuesday, August 6, 2013 - 9:09:07 PM
Last modification on : Tuesday, October 19, 2021 - 4:17:35 PM
Long-term archiving on: : Wednesday, April 5, 2017 - 7:44:34 PM